chr11-61393965-G-T

Variant summary

Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PM1PM2PM5PP5_Very_Strong

The NM_001173990.3(TMEM216):​c.218G>T​(p.Arg73Leu) variant causes a missense change. The variant allele was found at a frequency of 0.000123 in 1,613,752 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R73C) has been classified as Pathogenic.

Frequency

Genomes: 𝑓 0.00013 ( 0 hom., cov: 32)
Exomes 𝑓: 0.00012 ( 0 hom. )

Consequence

TMEM216
NM_001173990.3 missense

Scores

8
9
2

Clinical Significance

Pathogenic criteria provided, multiple submitters, no conflicts P:18O:1

Conservation

PhyloP100: 6.70
Variant links:
Genes affected
TMEM216 (HGNC:25018): (transmembrane protein 216) This locus encodes a transmembrane domain-containing protein. Mutations at this locus have been associated with Meckel-Gruber Syndrome Type 2, and Joubert Syndrome 2, also known as Cerebello-oculorenal Syndrome 2. [provided by RefSeq, Aug 2010]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Pathogenic. Variant got 14 ACMG points.

PM1
In a transmembrane_region Helical (size 20) in uniprot entity TM216_HUMAN there are 5 pathogenic changes around while only 0 benign (100%) in NM_001173990.3
PM2
Very rare variant in population databases, with high coverage;
PM5
Other missense variant is known to change same aminoacid residue: Variant chr11-61393964-C-T is described in Lovd as [Pathogenic].
PP5
Variant 11-61393965-G-T is Pathogenic according to our data. Variant chr11-61393965-G-T is described in ClinVar as [Pathogenic]. Clinvar id is 197.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr11-61393965-G-T is described in Lovd as [Pathogenic]. Variant chr11-61393965-G-T is described in Lovd as [Likely_pathogenic].

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
TMEM216NM_001173990.3 linkc.218G>T p.Arg73Leu missense_variant Exon 3 of 5 ENST00000515837.7 NP_001167461.1 Q9P0N5-1
TMEM216NM_001173991.3 linkc.218G>T p.Arg73Leu missense_variant Exon 3 of 5 NP_001167462.1 Q9P0N5-3
TMEM216NM_016499.6 linkc.35G>T p.Arg12Leu missense_variant Exon 3 of 5 NP_057583.2 Q9P0N5-2
TMEM216NM_001330285.2 linkc.35G>T p.Arg12Leu missense_variant Exon 3 of 5 NP_001317214.1 Q9P0N5J3QT25

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
TMEM216ENST00000515837.7 linkc.218G>T p.Arg73Leu missense_variant Exon 3 of 5 2 NM_001173990.3 ENSP00000440638.1 Q9P0N5-1
TMEM216ENST00000334888.10 linkc.218G>T p.Arg73Leu missense_variant Exon 3 of 5 2 ENSP00000334844.5 Q9P0N5-3

Frequencies

GnomAD3 genomes
AF:
0.000131
AC:
20
AN:
152146
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.00
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00432
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.0000735
Gnomad OTH
AF:
0.00
GnomAD3 exomes
AF:
0.000173
AC:
43
AN:
249228
Hom.:
0
AF XY:
0.000185
AC XY:
25
AN XY:
135212
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00338
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.0000531
Gnomad OTH exome
AF:
0.000496
GnomAD4 exome
AF:
0.000122
AC:
179
AN:
1461606
Hom.:
0
Cov.:
30
AF XY:
0.000128
AC XY:
93
AN XY:
727082
show subpopulations
Gnomad4 AFR exome
AF:
0.00
Gnomad4 AMR exome
AF:
0.00
Gnomad4 ASJ exome
AF:
0.00486
Gnomad4 EAS exome
AF:
0.0000756
Gnomad4 SAS exome
AF:
0.00
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.0000261
Gnomad4 OTH exome
AF:
0.000315
GnomAD4 genome
AF:
0.000131
AC:
20
AN:
152146
Hom.:
0
Cov.:
32
AF XY:
0.000121
AC XY:
9
AN XY:
74316
show subpopulations
Gnomad4 AFR
AF:
0.00
Gnomad4 AMR
AF:
0.00
Gnomad4 ASJ
AF:
0.00432
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.0000735
Gnomad4 OTH
AF:
0.00
Alfa
AF:
0.000271
Hom.:
0
Bravo
AF:
0.000162
ExAC
AF:
0.000132
AC:
16
EpiCase
AF:
0.000164
EpiControl
AF:
0.000119

ClinVar

Significance: Pathogenic
Submissions summary: Pathogenic:18Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Joubert syndrome 2 Pathogenic:7Other:1
Mar 28, 2024
Baylor Genetics
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Aug 19, 2019
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

The p.Arg73Leu variant (also called p.Arg12Leu) in TMEM216 is a founder variant in the Ashkenazi Jewish population and has been reported in the homozygous state in at least 20 individuals with Joubert syndrome or Meckel syndrome and segregated with disease in >10 affected individuals from at least 5 families (Edvardson 2010, Schueler 2016, Valente 2010). It has also been identified in 0.338% (35/10352) of Ashkenazi Jewish chromosomes by gnomAD (http://gnomad.broadinstitute.org). However, this frequency is low enough to be consistent with a recessive carrier frequency. This variant has been reported in ClinVar (Variation ID: 197). Computational prediction tools and conservation analyses do not provide evidence for or against pathogenicity. In vitro functional studies provide some evidence that this variant impacts protein function (Valente 2010); however, these types of assays may not accurately represent biological function. Additionally, two variants at the same position (p.Arg73His and p.Arg73Leu) have been identified in individuals with Joubert syndrome, suggesting that a change at this position may not be tolerated. In summary, the p.Arg73Leu variant meets criteria to be classified as pathogenic for autosomal recessive Joubert syndrome. ACMG/AMP criteria applied: PM3_Strong, PP1_Strong, PS3_Supporting. -

Mar 04, 2024
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

Variant summary: TMEM216 c.218G>T (p.Arg73Leu) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.00018 in 251116 control chromosomes The variant has been reported in multiple affected individuals presented with JBTS2 (e.g. Edvardson_2010, Valente_2010). This variant is considered to be a founder mutation in individuals of Ashkenazi Jewish descent. The carrier frequency in the Ashkenazi population was reported to be about 1:100 (Valente_2010). The following publications have been ascertained in the context of this evaluation (PMID: 20036350, 20512146). ClinVar contains an entry for this variant (Variation ID: 197). Based on the evidence outlined above, the variant was classified as pathogenic. -

Nov 12, 2019
Myriad Genetics, Inc.
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

NM_001173990.2(TMEM216):c.218G>T(R73L) is classified as pathogenic in the context of Joubert syndrome 2. Sources cited for classification include the following: PMIDs: 20036350, 20512146, and 22282472. Classification of NM_001173990.2(TMEM216):c.218G>T(R73L) is based on the following criteria: This is a well-established pathogenic variant in the literature that has been observed more frequently in patients with clinical diagnoses than in healthy populations. Please note: this variant was assessed in the context of healthy population screening. -

Feb 23, 2015
UW Hindbrain Malformation Research Program, University of Washington
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: research

- -

-
GeneReviews
Significance: not provided
Review Status: no classification provided
Collection Method: literature only

- -

Jul 01, 2010
OMIM
Significance: Pathogenic
Review Status: no assertion criteria provided
Collection Method: literature only

- -

Sep 16, 2020
Natera, Inc.
Significance: Pathogenic
Review Status: no assertion criteria provided
Collection Method: clinical testing

- -

not provided Pathogenic:5
Mar 15, 2024
Mayo Clinic Laboratories, Mayo Clinic
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

PP3, PP4, PM1, PM3, PS4 -

May 03, 2022
GeneDx
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

Published functional studies have reported a significant decrease in TMEM216 protein production in cells transfected with R73L compared to the wild type and ciliogenesis disruption in TMEM216-R73L mutated fibroblasts in affected individuals (Lee et al., 2012; Valente et al., 2010); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 22282472, 27065010, 27175728, 28125082, 31624327, 31663226, 20512146, 21029074, 20036350, 20301500, 26092869) -

Oct 26, 2017
Eurofins Ntd Llc (ga)
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Apr 10, 2023
Revvity Omics, Revvity
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Apr 01, 2021
CeGaT Center for Human Genetics Tuebingen
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

TMEM216-related disorder Pathogenic:2
Dec 14, 2018
Illumina Laboratory Services, Illumina
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

The TMEM216 c.218G>T (p.Arg73Leu) missense variant is noted to be a founder variant in the Ashkenazi Jewish population (Parisi et al. 2013). Across a selection of available literature, the p.Arg73Leu variant has been identified in a total of 40 individuals with Joubert syndrome including 39 homozygotes and one compound heterozygote. The variant was also identified in a heterozygous state in 119 unaffected family members (Edvardson et al. 2010; Valente et al. 2010; Bachmann-Gagescu et al. 2015). Additionally the p.Arg73Leu variant was found in a homozygous state in a Turkish family in which Meckel syndrome and Joubert syndrome coexisted within the same sibship (Valente et al. 2010). The p.Arg73Leu variant was reported in 30 of 2766 anonymous Ashkenazi Jewish individuals in a heterozygous state and is reported at a frequency of 0.003381 in the Ashkenazi Jewish population of the Genome Aggregation Database. Lee et al. (2012) reported that fibroblasts from a patient carrying the p.Arg73Leu variant showed failure of ciliogenesis. Based on the collective evidence, the p.Arg73Leu variant is classified as pathogenic for TMEM216-related disorders. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. -

Jun 21, 2024
PreventionGenetics, part of Exact Sciences
Significance: Pathogenic
Review Status: no assertion criteria provided
Collection Method: clinical testing

The TMEM216 c.218G>T variant is predicted to result in the amino acid substitution p.Arg73Leu. This variant has been reported as pathogenic in multiple patients with Joubert syndrome or Meckel syndrome (described as c.35G>T R12L, Edvardson et al. 2010. PubMed ID: 20036350; Valente et al. 2010. PubMed ID: 20512146; Table S5, Bachmann-Gagescu et al. 2015. PubMed ID: 26092869). This variant has been reported as a founder variant in the Ashkenazi Jewish population, and is reported in 0.34% of alleles in individuals of this descent in gnomAD. This variant is interpreted as pathogenic. -

Meckel syndrome, type 2 Pathogenic:1
Feb 29, 2016
Counsyl
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Inborn genetic diseases Pathogenic:1
Dec 01, 2022
Ambry Genetics
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

The c.218G>T (p.R73L) alteration is located in exon 3 (coding exon 3) of the TMEM216 gene. This alteration results from a G to T substitution at nucleotide position 218, causing the arginine (R) at amino acid position 73 to be replaced by a leucine (L). Based on data from gnomAD, the T allele has an overall frequency of 0.016% (44/280628) total alleles studied. The highest observed frequency was 0.338% (35/10352) of Ashkenazi Jewish alleles. The alteration has been previously reported in multiple individuals with Joubert syndrome from Ashkenazi Jewish families (Edvardson, 2010; Valente, 2010; Bachmann-Gagescu, 2015; Schueler, 2016). Additionally, other variants at this amino acid position have been reported to cause disease (Lee, 2012). This amino acid position is highly conserved in available vertebrate species. Functional analysis on patient fibroblasts demonstrated the p.R73L alteration disrupted ciliogenesis (Lee, 2012). This alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, this alteration is classified as pathogenic. -

Joubert syndrome 2;C1864148:Meckel syndrome, type 2 Pathogenic:1
Jan 06, 2024
Fulgent Genetics, Fulgent Genetics
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Familial aplasia of the vermis Pathogenic:1
Nov 18, 2024
Labcorp Genetics (formerly Invitae), Labcorp
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This sequence change replaces arginine, which is basic and polar, with leucine, which is neutral and non-polar, at codon 73 of the TMEM216 protein (p.Arg73Leu). This variant is present in population databases (rs201108965, gnomAD 0.4%). This missense change has been observed in individual(s) with Joubert syndrome (PMID: 20036350, 26092869). It is commonly reported in individuals of Ashkenazi Jewish ancestry (PMID: 20036350, 20512146). ClinVar contains an entry for this variant (Variation ID: 197). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. Experimental studies have shown that this missense change affects TMEM216 function (PMID: 20512146, 22282472). This variant disrupts the p.Arg73 amino acid residue in TMEM216. Other variant(s) that disrupt this residue have been observed in individuals with TMEM216-related conditions (PMID: 20512146), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
0.82
BayesDel_addAF
Pathogenic
0.43
D
BayesDel_noAF
Pathogenic
0.49
CADD
Pathogenic
27
DANN
Uncertain
1.0
DEOGEN2
Pathogenic
0.90
D;.;.
Eigen
Uncertain
0.31
Eigen_PC
Benign
0.19
FATHMM_MKL
Uncertain
0.92
D
LIST_S2
Uncertain
0.87
D;D;D
M_CAP
Pathogenic
0.46
D
MetaRNN
Uncertain
0.56
D;D;D
MetaSVM
Uncertain
0.77
D
MutationAssessor
Pathogenic
3.2
M;M;.
PrimateAI
Uncertain
0.56
T
PROVEAN
Pathogenic
-6.2
D;D;D
REVEL
Pathogenic
0.80
Sift
Uncertain
0.0020
D;D;D
Sift4G
Uncertain
0.010
D;D;D
Vest4
0.98
MVP
0.75
MPC
0.66
ClinPred
0.39
T
GERP RS
3.1
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.0
Varity_R
0.93
gMVP
0.93

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs201108965; hg19: chr11-61161437; COSMIC: COSV58426505; API